Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study

Documenti analoghi

• Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
  di: Gabriel Gárate, et al.
  Pubblicazione: (2024)
• Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
  di: Andrea M. Kuczynski, et al.
  Pubblicazione: (2025)
• Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
  di: Kara S. Graves, et al.
  Pubblicazione: (2026)
• Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
  di: Anna de Dios, et al.
  Pubblicazione: (2024)
• Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
  di: Samuel K. Peasah, et al.
  Pubblicazione: (2024)